Abstract
The increasing debate regarding the predictiveness of rodent persistent pain models for clinical efficacy has spurred rapidly evolving numbers and types of novel models from which to choose. While several excellent reviews of these models have been published in recent years, few focus on their specific applications and particular challenges with the use of these models in the setting of drug discovery. Thus, in this review, how models of persistent pain may be used to: 1) screen molecules for in vivo efficacy, 2) advance lead compounds and 3) guide decision making for clinical trial design is discussed. Relative to other disease areas for potential drug discovery and development, chronic pain appears to be well-poised for drug discovery and development. This is in large part due to the advanced understanding of pain mechanisms and the upsurge in the development of novel, specialized rodent models of persistent pain and improvements in methods of pain assessment in animals.
Keywords: Animal models, behavioral assays, behavioral pharmacology, drug discovery, in vivo efficacy models, pain models, predictive validity, translational research, rodent persistent pain models, clinical efficacy, persistent pain, upsurge, nerve injury, chronic inflammation
Current Pharmaceutical Biotechnology
Title: Rodent Models of Persistent Pain in Drug Discovery and Development
Volume: 12 Issue: 10
Author(s): William A. Eckert
Affiliation:
Keywords: Animal models, behavioral assays, behavioral pharmacology, drug discovery, in vivo efficacy models, pain models, predictive validity, translational research, rodent persistent pain models, clinical efficacy, persistent pain, upsurge, nerve injury, chronic inflammation
Abstract: The increasing debate regarding the predictiveness of rodent persistent pain models for clinical efficacy has spurred rapidly evolving numbers and types of novel models from which to choose. While several excellent reviews of these models have been published in recent years, few focus on their specific applications and particular challenges with the use of these models in the setting of drug discovery. Thus, in this review, how models of persistent pain may be used to: 1) screen molecules for in vivo efficacy, 2) advance lead compounds and 3) guide decision making for clinical trial design is discussed. Relative to other disease areas for potential drug discovery and development, chronic pain appears to be well-poised for drug discovery and development. This is in large part due to the advanced understanding of pain mechanisms and the upsurge in the development of novel, specialized rodent models of persistent pain and improvements in methods of pain assessment in animals.
Export Options
About this article
Cite this article as:
A. Eckert William, Rodent Models of Persistent Pain in Drug Discovery and Development, Current Pharmaceutical Biotechnology 2011; 12 (10) . https://dx.doi.org/10.2174/138920111798357456
DOI https://dx.doi.org/10.2174/138920111798357456 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
P2X4 Receptors of Microglia in Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Subject Index To Volume 12
Current Pharmaceutical Design Potential Utility of Self-Report Measures of Affect to Optimise Exercise Adherence in People with Type 2 Diabetes
Current Diabetes Reviews A Current Update on the Use of Alpha Lipoic Acid in the Management of Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Relative Survival Benefit and Morbidity with Fluids in Severe Sepsis - A Network Meta-Analysis of Alternative Therapies
Current Drug Safety Common Therapeutic Strategies for Diabetic Retinopathy and Glaucoma
Current Drug Therapy Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future
Current Pharmaceutical Design Oxidative Stress in the Pathogenesis/Treatment of Diabetes and its Complications
Current Nutrition & Food Science New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Current Pharmaceutical Design PDE-5 Inhibitors: Clinical Points
Current Drug Targets Factors Driving the Choice of the Best Second-Line Treatment of Advanced NSCLC
Reviews on Recent Clinical Trials An Improved Synthesis of m-Hydroxymexiletine, a Potent Mexiletine Metabolite
Drug Metabolism Letters Various Non-Injectable Delivery Systems for the Treatment of Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets NAD(P)H Oxidase Activation: A Potential Target Mechanism for Diabetic Vascular Complications, Progressive β-Cell Dysfunction and Metabolic Syndrome
Current Drug Targets Gabapentin-Mediated Effects on Voltage- and Ligand-Gated Currents
Current Neuropharmacology A Guide to Treatment of Sarcoidosis
Current Drug Therapy Poly(ADP-Ribosylation): Beneficial Effects of Its Inhibition
Current Enzyme Inhibition Aldose Reductase: A Multi-disease Target
Current Enzyme Inhibition Natural Products as α-Amylase and α-Glucosidase Inhibitors and their Hypoglycaemic Potential in the Treatment of Diabetes: An Update
Mini-Reviews in Medicinal Chemistry Endocrine Therapies and QTc Prolongation
Current Drug Safety